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Abstract  Cerebral  metastases  are  the  commonest  central  nervous  system  tumors.  The  MR
assessment  should  include  T1-weighted  images  with  and  without  enhancement  and  T2/FLAIR
images. They  usually  appear  as  multiple  lesions  with  nodular  or  annular  enhancement  and
are surrounded  by  edema.  They  are  hypervascularized  and  have  no  restriction  of  their  diffu-
sion coefﬁcient  in  their  necrotic  area  and  contain  lipids  on  1H  spectroscopy.  Metastases  can
be distinguished  from  primary  tumors  by  the  lack  of  malignant  cell  inﬁltration  around  the
tumor. Stereotactic  radiotherapy  may  temporarily  increase  tumor  volume,  although  this  is  not
of adverse  oncological  value.  Less  commonly,  spinal  disease  may  be  asymptomatic  and  should
be examined  by  MR.
© 2014  Published  by  Elsevier  Masson  SAS  on  behalf  of  the  Éditions  françaises  de  radiologie.
Changes  in  oncology  treatments  are  leading  to  increased  survival  of  cancer  patients  and
improved  quality  of  survival,  even  in  those  with  metastases.  The  diagnostic  and  treatment
approach  to  cerebral  metastases  is  becoming  an  increasingly  common  problem.
Intracranial metastases
Epidemiological ﬁndings
Cerebral  metastases  (CM)  have  become  a  public  health  problem.  They  have  increased  in
incidence  in  recent  years  because  of  improved  oncology  treatments  in  parallel  with  the
advances  in  medical  imaging,  which  now  offers  optimal  screening  for  CM.
Smedby  [1]  reported  a doubling  in  the  incidence  of  CM  in  Sweden  between  1987  and
2006,  without  a  doubling  in  cases  of  related  primary  malignancy.
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This  incidence  depends  on  the  histological  type  of  the  pri-
ary  cancer:  20%  for  lung  cancer,  7%  for  melanoma,  6.5%  for
enal  cancer,  5.1%  for  breast  cancer  and  1.8%  for  colorectal
ancer  [2].
The  prevalence  of  CM  in  patients  suffering  from  cancer
s  estimated  to  be  10%.
Cerebral  involvement  requires  circulating  tumor  cells  to
dhere  to  the  cerebral  endothelium  resulting  in  invasion  of
he  parenchyma  and  then  in  situ  growth.  Some  prolifera-
ion  factors  for  CM  are  speciﬁc  to  the  tumor  cells  and  others
epend  on  the  environment.  Blood  ﬂow,  for  example,  inﬂu-
nces  the  site  of  CM.
Cerebral  hemisphere  disease  is  the  most  common  (80%)
nd  the  CM  are  located  preferentially  in  the  white  matter  —
rey  matter  junction.  This  is  followed  by  cerebellar  (15%),
hen  brain  stem  involvement  (3%).
In  this  context,  we  shall  also  consider  spread  of  central
ervous  system  tumors  through  cerebrospinal  ﬂuid.  Whilst
hese  metastases  are  well  known  for  medulloblastoma  or
pendymoma  and  require  routine  screening  in  these  diag-
oses,  they  are  also  classically  seen  with  high-grade  gliomas
ith  periventricular  ependymal  enhancement  and  a  blurring
f  the  subarachnoid  spaces  at  the  base  of  the  cranium.
linical aspects
he  predominant  clinical  feature  is  headache  initially  in  the
orning  and  becoming  permanent,  and  may  be  combined
ith  raised  intracranial  pressure.  Neurological  deﬁcit  and
eterioration  of  higher  functions  may  also  be  the  presenting
eatures  of  secondary  disease.
igure 1. Enhanced T1 axial MR (a, b, c) and cerebral blood volume ma
nhancement. These are hypervascular on the cerebral blood volume m
1
c
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CM  may  also  be  silent  and  found  in  the  routine  staging
ssessment  for  a primary  tumor.
maging CM
adiological  investigations  may  form  either  part  of  the  rou-
ine  staging  assessment  for  a  known  malignancy  or  are  used
hen  a  metastases  is  discovered  as  the  presenting  feature
f  cancer.  Although  computed  tomography  is  still  used  to
creen  for  CM,  MR  clearly  appears  to  be  the  most  sensitive
etection  investigation.
Intraparenchymal  metastasis  (Fig.  1),  which  are  the
ost  common,  usually  appear  as  nodular  images  which  are
ypointense  on  T1-weighted  and  hyperintense  on  T2/FLAIR
mages,  with  annular  or  nodular  enhancement  surrounded
y  ‘‘ﬁnger  gloves’’  edema  which  is  often  disproportionate
o  the  size  of  the  lesion  itself  (Fig.  2).
First-pass  perfusion  ﬁndings  show  a  cerebral  blood  vol-
me  ratio  (rCBV=  CBV metastases/CBV healthy white matter),  which
s  raised  [3]  to  2  or  above.  Average  values  depend  on  the
maging  sequence  used,  the  power  of  magnetic  ﬁeld  and  the
resence  of  blood  and  calciﬁcations  impeding  the  perfusion
tudy  because  of  multiple  magnetic  susceptibility  artifacts.
On 1H  spectroscopy  (Fig.  3),  a metastasis  displays
ncreased  choline  and  reduced  N-acetylaspartate  (NAA)  res-
nance  whereas  large  amount  of  lipids  (resonances  centered
t  0.9  and  1.3  ppm)  and  lactate  (a  doublet  centered  atpping (d): showing multiple rounded lesions with massive contrast-
apping, suggesting secondary disease.
.3  ppm),  particularly  if  necrosis  is  present.
Diffusion-weighted  images  are  used  to  examine  tumor
ellularity  and  exclude  a  possible  pyogenic  abscess
Fig.  4),  as  intraparenchymal  disease  may  take  on  different
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Figure 2. Left anterior frontal metastasis from a lung cancer, annular in appearance after contrast-enhancement (a) surrounded by a
very large amount of ﬁnger glove edema clearly visible on FLAIR MR (b). The extent of the edema is a usual ﬁnding in metastases.
ma (
y anoFigure 3. Single right cerebellar metastasis surrounded by ede
spectroscopy view as positive resonance centered at 1.3 ppm and bappearances  depending  on  whether  tit  are  nodular  or  more
or  less  necrotic  and  cystic.
Some  appearances  may  point  towards  the  origin  of  the
primary  malignancy.  Metastases  from  melanoma  may  be
h
a
m
a
Figure 4. Metastases may take on all guises: in this case a cystic app
image (a); the lesions are very hyperintense on T2-weighted images (b
possibility of infectious causes.a and b) containing large amount of lipids shown on a long TE
ther resonance centered at 0.9 ppm.yperintense  on  unenhanced  T1-weighted  images  (Fig.  5)  as
 result  of  melanin  deposition  or  hemorrhage.  Hemorrhagic
etastases  are  often  associated  with  choriocarcinoma
nd  renal  cancer.  Cystic  appearances  are  often  seen  in
earance of a very slight peripheral enhancement on the enhanced
), with an increase in the diffusion coefﬁcient (c) excluding the
920  
Figure 5. Metastases from a melanoma may be hyperintense
on an unenhanced T1-weighted view: a ‘‘shower’’ of nodular
micrometastases.
a
V
t
c
h
1
t
i
a
i
c
s
c
b
t
i
h
w
n
Figure 6. Sudden onset neurological deﬁcit in a 65-year-old man wit
a cerebrovascular accident and investigated with a view to thrombolys
gradient image (a) surrounded by a large amount of edema on FLAIR MR
doubt on the diagnosis of hypertensive hematoma on the 3D T1-weigh
computed tomography the lesion enhances peripherally. This is a single m
within the tumor.S.  Grand  et  al.
denocarcinoma  metastases  (lung,  colon  and  breast,  etc.).
ery  hypervascular  tumors  on  perfusion  imaging  points
owards  lesions  secondary  to  a  melanoma  or  renal  adeno-
arcinoma  [4].
A  sudden  neurological  deﬁcit  is  occasionally  explained  by
emorrhage  within  a  metastases  (Fig.  6).
Meningeal  metastases  (Fig.  7) account  for  approximately
0%  of  intracranial  metastases.  These  complicate  both  solid
umors,  leukemias  and  lymphomas.  The  typical  appearance
s  one  of  gyriform  enhancement  producing  a  sheet  like
ppearance  in  the  meninges.  These  lesions  are  seen  both
n  the  convexity  and  in  the  base  of  the  cranium  and  may
ause  hydrocephalus  (Fig.  8) by  blocking  the  subarachnoid
paces.  Another  nodular  form  is  seen  with  spread  of  tumor
ells  along  the  cerebrospinal  ﬂuid.
Dural  metastases  (Fig.  9) are  rarer  and  usually  involve
one  disease  extending  to  the  dura  mater.  In  some  cases
he  dual  disease  predominates,  occasionally  resulting  in  an
ncorrect  diagnosis  of  meningioma.  Spectroscopy  is  useful
ere  as  in  meningiomas  the  spectrum  contains  only  choline
hereas  lipid  resonances  are  seen  with  metastases  (Fig.  10).
Regardless  of  site,  the  vault  and  the  base  of  the  cra-
ium  must  be  examined  to  look  for  related  bony  metastases.
h no past history. The patient was suspected clinically of having
is. His assessment showed a hematoma on the T2-weighted echo-
 (b). CT at 24 hours (c) showed a slightly hyperdense lesion casting
ted enhanced echo-gradient axial view (d) performed after the
etastasis from a lung adenocarcinoma presenting with hemorrhage
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Figure 7. Meningeal disease in the cerebellum complicating breast cancer, clearly visible on these 2 enhanced T1-weighted images (a and
b).
Figure 8. Female patient followed up for breast cancer with lung and liver metastases presenting with headaches. The FLAIR image (a)
shows ventricular dilatation with signs of transependymal resorption. The T1-weighted axial views with fat suppression after gadolinium (b
and c) show meningeal carcinomatosis at the base of the cranium with slight enhancement of the superior vermis and the two auditory-facial
nerve bundles.
Figure 9. Bulky left, parieto-occipital bone metastasis with extension subcutaneously and to the dura mater appearing as an enhancing
mass (a) with clearly demarcated borders and no underlying edema on the T2-weighted image (b).
922  S.  Grand  et  al.
Figure 10. Acute epilepsy in a patient with a past history of ethmoid carcinoma. Bulky left anterior extra-parenchymal frontal mass
pushing back the cerebral parenchyma on the T2-weighted coronal view combined with bilateral involvement of the white matter following
treatment (a), with massive contrast-enhancement on the enhanced T1-weighted axial view (b) with enhancement remote from the dura
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f metastasis.
hilst  this  investigation  is  ‘‘reﬂex’’  in  computed  tomogra-
hy,  it  is  occasionally  omitted  in  MR  investigations  (Fig.  11).
nvestigation protocol
he  current  preferred  technique  to  investigate  cerebral
etastases  is  magnetic  resonance  imaging.  This  has  two
ifferent  aims:
In  known  malignancy, the  purpose  of  MR  is  to  identify
nd  locate  all  of  the  secondary  disease  for  optimal  patient
anagement.  The  development  of  stereotactic  radiosurgery
Gamme  knife  or  Cyber  knife)  or  arc-therapy  (linear  accel-
rator)  techniques  enables  local  high  dose  irradiation  to  a
aximum  of  3  lesions  under  3  cm  in  size.  This  approach
herefore  changes  management  of  secondary  disease,  which
ntil  now  has  involved  panencephalic  irradiation  with  or
ithout  chemotherapy.
In unknown  malignancy, the  aim  of  MRI  is  to  make  a  pos-
tive  diagnosis  of  secondary  disease,  which  may  be  difﬁcult
ith  a  single  lesion  and  is  discussed  in  the  ‘‘Differential
iagnoses’’  paragraph.
T
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igure 11. Staging assessment for a melanoma with left inferior cerebe
nhances (b) and is seen clearly on computed tomography (c).m, excluding a diagnosis of meningioma and supporting a diagnosis
The  investigation  protocols  ﬁrstly  involve  a  T1-weighted,
nenhanced  sequence  in  order  to  recognize  hemorrhagic
etastases,  which  are  hyperintense  without  enhancement,
r  metastases  from  a  primary  melanoma,  which  contain
elanin  and  may  occasionally  by  hyperintense.
A  contrast-enhanced  series  must  be  taken.  The  standard
ose  is  0.1  mmol/kg  of  gadolinium  complex,  or  0.2  ml/kg.
Using  a  double  dose  is  more  expensive  but  better  identi-
es  small  metastases  as  it  has  been  known  for  many  years
5]  that  a  double  or  even  triple  dose  improves  detection
f  small  lesions.  The  merits  of  the  double  dose  was  further
ighlighted  in  2010  by  KIM  [6]  who  compared  dimeglutamine
adopentate  (Magnevist®) and  gadobutrol  (Gadovist®),  both
sed  at  double  doses,  whereas  the  molecular  concentration
n  Gadovist® is  already  twice  that  of  Magnevist®.
It  is  important  to  leave  an  interval  between  contrast
njection  and  image  acquisition  [5]  in  order  to  allow  the  con-
rast  medium  time  to  diffuse  before  recording  the  images.
his  is  particularly  a  crucial  factor  when  a  T1-weighted  vol-
me  image  is  recorded.
For  this  reason  it  is  recommended  that  a  T2/FLAIR
equence  be  taken  after  gadolinium  enhancement  in  order
llar metastasis (a). Note the right parietal bone involvement which
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to  allow  a  few  minutes  before  the  T1-weighted  image  is
taken.
This  is  performed  from  a  volume  acquisition  usually  in
echo-gradient  mode,  which  provides  good  contrast  between
the  white  and  grey  matter  and  is  available  on  most  machines
or  from  a  spin  echo  volume  acquisition.  This  sequence  is
reported  to  have  some  advantages  in  detecting  secondary
diseases  [7].
Many  sequences  are  currently  being  developed  to  opti-
mize  detection  of  small  peripheral  lesions  including  a  3D  spin
echo  ‘‘blood  sequence’’  in  order  not  to  confuse  peripheral
vascular  enhancement  with  a  small  metastasis  [8].
FLAIR  images  detect  small  cortico-subcortical  lesions
(Fig.  12).
A FLAIR  series  after  gadolinium  enhancement  has  also
raised  hopes  in  identifying  meningeal  disease,  helping  to
reduce  the  T1-weighted  relaxation  time  for  image  enhance-
ment  due  to  the  removal  of  the  cerebrospinal  ﬂuid  image
signal  and  the  lack  of  enhancement  of  normal  cortical  ves-
sels.
Finally,  Singh  [9]  highlighted  that  enhanced  T1-weighted
images  were  more  sensitive  than  enhanced  FLAIR  to  detect
meningeal  metastases.Some  people  [10]  recommend  an  enhanced  T1-weighted
series  with  fat  suppression  rather  than  an  enhanced  FLAIR
series.  More  recently  one  group  [11]  has  highlighted  the
utility  of  3D  sequences  after  gadolinium.
g
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Figure 12. FLAIR images are particularly useful to identify cortico-sub
for lung cancer a small left subcortical insular hyperintensity is seen on
(b). The early repeat shows an increase in volume of the lesion on the FL
injection (d).923
Advanced  imaging  has  a  role  in  diagnostic  difﬁculties,
articularly  to  identify  a  single  mass  in  a  patient  with  no
ast  history  of  malignancy.
ifferential diagnoses
etastases  versus  malignant  glioma
oth  of  these  malignant  tumors  are  extremely  similar
orphologically  and  both  appear  as  contrast-enhancement
hich  is  usually  annular  or  nodular  surrounded  by  a  large
mount  of  edema  (Fig.  13).  Both  tumors  have  an  increased
CBV  on  perfusion  imaging  and  increased  choline  with  lac-
ate  and  lipid  present  on  spectroscopy.
Discriminating  between  the  two  tumors  is  particularly
ifﬁcult  when  the  lesion  is  single  and  the  patient  has  no
nown  past  history  of  malignancy.
Some  subtle  appearances  suggest  a  glial  tumor.  These
nclude  a  hyperintensity  inﬁltrating  the  cortex  on  FLAIR
maging  [12].  Extension  to  the  corpus  callosum  or  opti-
al  tract  also  points  towards  a glial  tumor.  Analysis  of  the
egion  around  the  tumor  is  the  most  appropriate  method  to
ndicate  one  or  other  of  these  two  causes.  The  hyperinten-
ity  on  FLAIR  imaging  around  the  contrast-enhancement  in
liomas  reﬂects  both  edema,  the  presence  of  tumor  cells  and
umor  capillaries  (inﬁltration  around  the  lesion)  whereas  the
yperintensity  on  FLAIR  imaging  around  a  metastases  only
eﬂects  vasogenic  edema  (edema  around  the  lesion).
cortical lesions. In the initial assessment of a patient followed up
 FLAIR MR (a) very slightly enhancing on the image with contrast.
AIR (c) view and contrast uptake, this time annular, after contrast
924  S.  Grand  et  al.
Figure 13. Around a contrast enhancing annular metastasis (a), edema around the lesion is only visible on FLAIR MR, with no tumor
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cnﬁltration (b). Conversely, around a left frontal glioblastoma wh
osterior margin (arrow) and ‘‘ﬁnger gloves’’ edema is seen around
This  difference  is  seen  on  both  perfusion  and  spec-
roscopy  imaging.  The  rCBV  ratio  surrounding  the  lesion
round  malignant  gliomas  is  greater  than  around  metas-
ases  and  in  the  same  way  the  Cho/Cr  ratio  is  higher  around
alignant  gliomas  than  around  metastases  [13].  An  increase
n  myoinositol  around  a  malignant  glioma  has  also  been
eported  more  recently  [14].  According  to  Opstad  [15],  a
etailed  analysis  of  lipids  in  the  form  of  a  ratio  centered  at
.3  ppm  and  resonances  centered  at  0.9  ppm  may  differen-
iate  metastases  from  malignant  gliomas.
Cha  [16]  has  examined  perfusion  curves  using  two  param-
ters:  peak  height  and  percentage  signal  recovery.  The  peak
eight  correlates  closely  with  cerebral  blood  volume  and  is
igher  around  a  high-grade  lymphoma  than  around  metas-
ases.  The  percentage  recovery  of  signal  intensity  is  lower
round  a  metastasis  than  around  a  glioblastoma  reﬂect-
ng  the  highly  patent  micro  vessels.  Recently,  Ducreux  [17]
eported  the  utility  of  a  dynamic  T2-weighted  echo-gradient
equence,  which  shows  an  increased  rCBV  and  permeabil-
ty  abnormalities  (examined  by  measuring  the  R2*)  in  the
lose  peritumor  tissue  in  gliomas  and  not  in  metastases.
In  practice,  the  ﬁnding  of  hyperperfused  areas  on
he  cerebral  blood  volume  mapping  (obtained  from  a
rst-pass  perfusion  sequence)  beyond  the  area  of  contrast-
nhancement  argues  in  favor  of  a  malignant  glioma  rather
han  a  secondary  disease.
Multiparametric  MR  approaches  [18]  are  developing
o  distinguish  high-grade  gliomas  from  metastases.  This
t
o
1s also necrotic and cystic (c), tumor inﬁltration is present at its
lesion (d).
nvolves  examining  the  texture  of  different  tissues  by
xtracting  parameters  such  as  entropy  and  homogeneity  etc.
rom  a  perfusion  series.  This  complex  approach  appears  to
e  promising  and  merits  being  developed.
etastases  versus  cerebral  abscess
bisu  [19]  has  shown  the  importance  of  diffusion-weighted
equences  to  distinguish  abscesses  from  necrotic-cystic
umors  as  abscesses  have  a lower  diffusion  coefﬁcient  than
umors  (Fig.  14).
This  technique  is  of  course  not  pathognomonic  for  the
iagnosis  of  cerebral  abscess  although  it  is  very  relevant  with
 sensitivity  and  speciﬁcity  of  96%  to  distinguish  cerebral
bscesses  from  non-abscess  space  occupying  lesions.  It  has
 positive  predictive  value  of  98%  and  a  negative  predictive
alue  of  92%.
The  diffusion-weighted  technique  in  particular  may  fail
ith  false  positives  such  as  hemorrhagic  metastases  and
alse  negatives  when  antibiotic  therapy  has  been  started  or
n  fungal  abscesses.
In these  situations  it  may  be  useful  to  use  spectroscopy,
hich  demonstrates  the  presence  of  an  amino  acid  peak
entered  at  0.9  ppm  in  pyogenic  abscesses  [20].
Castillo  [21]  proposed  diffusion  tensor  imaging  to  avoid
he  need  for  ADC  analysis.
Mapping  of  the  anisotropic  fraction  shows  the  presence
f  a  hyperintense  ring  in  84.6%  of  metastases  and  in  only
3.3%  of  abscesses.  In  parallel,  the  extent  of  anisotropism
The  different  faces  of  central  nervous  system  metastases  925
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pFigure 14. The liquid component of cystic metastases (a) have a ra
the liquid component of multiple pyogenic abscesses (c) has a red
fundamental to distinguish multiple metastases from abscesses.
measured  by  various  indicators  relating  to  the  differences
between  the  speciﬁc  values  of  the  tensor  may  point  towards
one  or  other  cause.
More  simply,  studying  the  capsule  of  the  lesion  may  help
to  distinguish  between  malignant  tumors  and  abscesses.
Abscesses  have  a  capsule,  which  is  rich  in  collagen  and
poorly  vascularized  with  a  rCBV  of  close  to  1  [22]  often
passing  above  the  ﬁrst-pass  curve  baseline.
Finally,  susceptibility  imaging  [23]  used  for  abscesses
shows  two  concentric  rings,  one  hyperintense  and  the
other  hypointense  around  the  collection.  An  external  thin
complete  hypointense  capsule  believed  to  represent  para-
magnetic  free  radical  deposits  from  macrophages  and  the
internal  hyperintense  ring  reﬂecting  the  granulomatous  tis-
sues,  which  are  usually  present  between  the  necrotic  centre
of  the  abscess  and  the  ﬁbrous  collagen  capsule.
Although  none  of  these  techniques  is  speciﬁc  to  identify
infection,  the  diagnosis  can  often  be  made  appropriately
because  of  the  wide  range  of  techniques  available.
Metastases  versus  lymphoma
Primary  cerebral  lymphoma  appears  typically  as  a  homo-
geneous  band,  which  is  hyperdense  on  unenhanced  CT,
hypointense  on  T1-weighted  imaging  in  the  cortex  and  more
hypointense  on  T2-weighted  imaging  with  massive  contrast
uptake.  Whilst  a  single  deep  lesion  in  the  corpus  callosum
requires  little  discussion,  multiple  sites  beneﬁt  from  being
examined  by  diffusion-weighted  and  perfusion  images  in
order  to  distinguish  these  from  metastases.
(
t
e diffusion coefﬁcient on the corresponding mapping (b). Conversely,
 ADC on mapping (d). The diffusion-weighted views are therefore
Lymphoma  is  highly  cellular  and  has  a  low  diffusion  coef-
cient:  the  malignant  blood  vessels  are  patent,  fenestrated
nd  the  rCBV  is  slightly  higher,  close  to  1  passing  well  above
he  ﬁrst-pass  curve  baseline  on  investigations  performed  at
.5  Tesla  (Fig.  15)  [24].  It  passes  above  the  baseline  less
ften  at  3  T  [25].
The  typical  spectrum  is  that  of  a  choline  peak  combined
ith  lipid  resonances  centered  at  1.3  and  0.9  ppm  outside  of
ecrotic  areas  [26,27].  These  lipid  resonances  are  believed
o  be  due  to  the  presence  of  numerous  macrophages  con-
aining  lipid  droplets.
The  advanced  techniques  are  particularly  useful  to  iden-
ify  primary  or  secondary  meningeal  lymphomas.
The  diagnosis  may  be  difﬁcult  in  immunosuppression,  as
ymphomatous  masses  in  this  situation  may  appear  multiple
nd  necrotic  and  can  take  on  appearances  very  similar  to
econdary  disease.  Here  again,  perfusion  ﬁndings  are  very
ontributive  in  order  to  distinguish  lymphoma  from  metas-
asis.
reatment follow-up
he  treatment  follow-up  for  a  cerebral  metastasis  usually
aises  no  problem  if  the  patient  has  received  chemo-  and/or
anencephalic  radiotherapy  as  the  fall  in  tumor  volume
RECIST  criteria)  reﬂects  a  positive  response  to  treatment.
A  more  difﬁcult  problem  arises  in  following  up  metas-
ases,  which  have  been  irradiated  by  radiosurgery.  Increased
arly  resolving  contrast-enhancement  has  been  shown  to
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Figure 15. Multiple periventricular lesions with massive contrast-enhancement (a and b), with a cerebral blood volume ratio of 1.5 on
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The perfusion curve (c) and particularly, major patency abnormali
OI, yellow curve, lymphoma ROI blue curve). This is a primary cen
e  present  in  12%  of  cases  [28].  This  appearance  is  seen
articularly  in  young  people  and  if  chemotherapy  has  been
ombined  with  radiosurgery.
Patel  [29]  examined  the  tumor  volume  of  516  metas-
ases  treated  by  radiosurgery  over  3  years  and  showed  that
 third  of  the  lesions  increased  in  size  during  their  follow-
p.  This  increase  in  volume  begins  from  6  weeks  after  the
adiosurgery  and  can  last  for  up  to  15  months  afterwards.
ize  criteria  may  therefore  not  be  sufﬁcient  to  distin-
uish  radionecrosis  from  recurrence  of  tumor.  Histologically,
ecrotic  reactions  have  been  found  associated  with  inﬂam-
ation,  gliosis  effects  and  demyelination.
Kano  [30]  proposes  that  T1-weighted  contrast-
nhancement  be  compared  to  the  appearance  of  the
esion  on  T2-weighted  imaging.  If  the  margins  of  the  tumor
eﬁned  from  T1-weighted  imaging  cut  through  the  margins
f  the  T2  image  of  the  tumor,  the  appearance  suggests
umor  recurrence  whereas  if  contrast-enhancement  over-
aps  the  image  abnormalities  which  then  are  blurred  on
2-weighted  imaging,  the  appearance  should  rather  suggest
adionecrosis.
Perfusion  imaging  also  has  a  role  in  monitoring  malignant
lioma.  A  raised  rCBV  suggests  progressive  tumor  whereas  a
elatively  low  ratio  suggests  radionecrosis.
pinal metastasesntraspinal metastases [31]
pinal  metastases  are  poorly  understood  and  may  occur
s  a  complication  of  an  initial  tumor  located  either  inside
c
s
o
leen by the baseline passing above the ﬁrst-pass curve (reference
ervous system lymphoma.
r  outside  of  the  CNS.  MR  is  the  only  investigation  which
hould  be  used  to  investigate  for  these.  A  recent  article
32]  has  reviewed  the  clinical  and  radiological  features  of
5  patients:  spinal  signs  were  the  presenting  feature  of  the
alignancy  in  20%  of  cases  although  in  8%  the  metastases
ere  asymptomatic.  Lesions  enhanced  with  contrast  in  98%
f  cases,  multiple  lesions  were  present  in  20%  of  cases  and
imilarly  to  cerebral  metastases  they  had  extensive  edema
preading  over  more  than  3  vertebral  segments.  Concom-
tant  bone  metastases  are  common  and  must  be  looked
or.
The  main  differential  diagnosis  is  with  a  primary  CNS
umor.  Rykken  [31]  described  two  appearances  which
ointed  towards  metastatic  disease  (other  than  pri-
ary  CNS  malignancy).  The  ‘‘ring  sign’’  (a  complete
r  incomplete  enhancement  ring  outside  of  the  cen-
ral  contrast-enhancement)  and  the  ‘‘ﬂame  sign’’  (poorly
eﬁned  enhancement  in  the  upper  or  lower  pole  of  the  lesion
ooking  like  a  spark)  (Fig.  16).
pidural, subdural and meningeal metastases
nvestigation  with  enhancement  should  include  the  roots  of
he  cauda  equina  and  the  end  of  the  dural  sac  and  should
ot  stop  at  the  conus  medullaris  (Figs.  17,  18  and  19).
Meningeal  disease  appears  as  nodular  contrast  uptake
long  the  axis  of  the  spine  and  cauda  equina  nerve  roots.
he  dura  mater  may  be  involved  either  in  isolation  or  may
omplicate  bone  metastases  and  often  appears  as  a  spindle-
haped  lesion  which  compresses  the  spinal  cord  to  a  greater
r  lesser  extent.  Concomitant  bone  metastases  must  be
ooked  for  routinely.
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Figure 16. Intraspinal metastasis from a breast cancer. Note the ﬂame appearance of contrast-enhancement in the upper pole of the
lesion (a) and the considerable edema around the lesion on the T2-weighted image (b).
Figure 17. Left posterior epidural metastases from a lung adenocarcinoma. Contrast-enhancement is heterogeneous on the T1-weighted
sagittal view (a), and the mass is pushing the spinal cord forwards on the T2-weighted axial view (b).
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Figure 18. ‘‘Hazy’’ images seen on T2-weighted imaging (a), created by the cerebrospinal ﬂuid hyperintensity on T2, enhancing on the
T1-weighted view with fat suppression (b) reﬂecting meningeal metastases from a breast cancer.
Figure 19. Contrast-enhancement which is subdural (a) and bilobulated (b) representing extension of a medulloblastoma.
929
•  The  peritumor  environment  must  be  analyzed  in
detail  to  differentiate  primary  tumors  from  cerebral
metastases.
•  Diffusion-weighted  imaging  distinguishes  metastases
from  multiple  pyogenic  abscesses.
•  The  ﬂame  sign  and  the  ring  sign  help  to  distinguish
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Conclusion
Cerebral  metastases  are  varied  in  appearance  and  should
always  be  considered  in  patients  with  a  past  history  of
malignancy  or  with  multiple  lesions.  Advances  in  treatment
options  make  an  optimal  radiological  assessment  essential,
occasionally  using  advanced  techniques.  Knowledge  of  the
treatment  regimens  used  is  required  to  interpret  post  radio-
chemotherapy  ﬁndings.  Spinal  lesions  (apart  from  extension
of  bone  metastases)  are  often  missed  and  very  rarely  looked
for  routinely,  whereas  they  may  be  asymptomatic.
TAKE-HOME  MESSAGES
• Any  cerebral  lesion  should  suggest  a  metastasis  in
patients  with  a  past  history  of  malignancy.
• Cerebral  metastases  are  often  multiple  but  may
be  single.  MR  is  the  most  sensitive  investigation  to
diagnose  these.
• Perfusion,  diffusion  and  spectroscopy  distinguish
metastases  from  non-malignant  structures
(abscesses,  granulomatosis,  etc.). T
w
Figure 20. Axial FLAIR view (a), ADC mapping (b), T1-weighted enhanintraspinal  metastases  from  a  primary  malignancy.
linical case
 seventy-seven-year-old  female  patient  was  hospitalized
or  a  ﬁrst  attack  of  epilepsy.  Clinical  examination  revealed
 right  breast  mass  (Fig.  20).
uestions
hat  do  you  think  of  this  MR?  What  diagnosis  would
ou  make  from  examination  of  the  FLAIR  and  enhanced
1-weighted  appearances  and  the  perfusion  and  diffusion-
eighted  images?
ced axial view (c and d) and CBV mapping (e).
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nswer
ultifocal  glioblastoma
here  are  several  parietal  lesions  grouped  in  clusters,  which
re  heterogeneous  with  a  necrotic  centre  and  increased  dif-
usion  coefﬁcient,  which  excludes  the  diagnosis  of  cerebral
bscess.  The  lesions  are  hypervascular  and  in  particular,
he  perfusion-weighted  abnormalities  go  beyond  the  T1-
eighted  contrast-enhancement,  particularly  anteriorly.
These  appearances  primarily  suggests  a  malignant  glioma
ather  than  secondary  disease,  despite  the  breast  mass.
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